Condition: Solid Tumor · Sponsor: Nanjing Immunophage Biotech Co., Ltd
This is a phase 1, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD) characteristics and initial anti-tumor activity of IPG1094 in patients with advanced solid tumors. The study will be conducted in two parts: dose escalation phase (Part A) and expansion phase (Part B).
This description comes directly from the study's public registry record.
Filipe Huang · +8621 34782827 · yfhuang@immunophage.com.cn
Yang Hu · +8621 34782827 · yhu@immunophage.com.cn
Always discuss trial participation with your own doctor first.
| Shanghai General Hospital | Shanghai, Shanghai Municipality, China | Recruiting |
| Shanghai GoBroad Cancer Hospital China Pharmaceutical University | Shanghai, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06212076